khondrion logo

Khondrion B.V

Khondrion's team aims to make a substantial contribution to the development of a cure for mitochondrial disease and related disorders. Khondrion is a clinical stage pharma company developing therapies for inherited mitochondrial diseases, including Leigh Disease, MELAS, Lebers Hereditary Optic Neuropathy and other Respiratory Chain / Oxidative Phosphorylation disorders.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.khondrion.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
PO BOX 9101M357.00.1326500 HB
Nijmegen
Netherlands
Email
Contact Number
+31 24 361 75 05

Khondrion has strategic partnership with the Nijmegen Centre for Mitochondrial Disorders of the Radboud University Medical Centre, Nijmegen, The Netherlands, to access all mitochondrial tools, technologies and expertise.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/khondrion” connections=”true” suffix=””]

Khondrions proprietary technology platform lies on cell-based disease models built upon a panel of primary human cell lines with different degrees of impairment in their energy production system.

Sep 2016, Khondrion received 1 mEuro grant from European Union EFRO to boost the development of Khondrions KH176

Khondrion is supported by the Dutch Foundations Energy4All, Join4Energy, Ride4Kids, Road4Energy, Tim Foundation, Zeldzame Ziekten Fonds, the Prinses Beatrix Fonds, and National (NWO, ALW, ZonMW) and European Governments (Marie-Curie ITN, Eurostars).